Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Design Therapeutics, Inc. (DSGN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/25/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results|
Docs:
|
"DESIGN THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 17,064 $ 11,295 $ 32,794 $ 20,054 General and administrative 5,532 4,344 11,453 8,955 Total operating expenses 22,596 15,639 44,247 29,009 Loss from operations Other income, net 2,659 640 5,016 745 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average shares of common stock outstanding, basic and diluted 55,948,990 55,670,780 55,928,625 55,589,510 DESIGN THERAPEUTICS, INC. CONDENSED BALANCE SHEETS June 30, December 31, 2023 2022 Assets Current assets: Cash, cash equivalents and investment securities $ 303,088 $ 330,387 Prepaid expense and other current assets 2,957 4,732 Total curren..." |
|
| 06/01/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"DESIGN THERAPEUTICS, INC. CONDENSED BALANCE SHEETS March 31, December 31, 2023 2022 Assets Current assets: Cash, cash equivalents and investment securities $ 315,392 $ 330,387 Prepaid expense and other current assets 3,547 4,732 Total current assets 318,939 335,119 Property and equipment, net 1,905 1,947 Right-of-use asset, related party 3,447 3,612 Other assets 452 459 Total assets $ 324,743 $ 341,137 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 2,744 $ 3,025 Accrued expenses and other current liabilities 6,303 7,751 Total current liabilities 9,047 10,776 Operating lease liability, net, related party 2,878 3,051 Total liabilities 11,925 13,827 Total stockholders’ equity 312,818 327,310 Total liabilities and stockholders’ equity $ 324,743 $ 341,137 DESIGN TH..." |
|
| 04/13/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/13/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/03/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.1% stake in Design Therapeutics, Inc. |
| 03/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 9.2% stake in Design Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/03/2023 |
SC 13G
| BlackRock Inc. reports a 6.3% stake in DESIGN THERAPEUTICS INC |
| 12/22/2022 |
SC 13D/A
| SR One Capital Fund I Aggregator LP reports a 11.7% stake in Design Therapeutics, Inc. |
| 12/22/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/13/2022 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 5.3% stake in DESIGN THERAPEUTICS, INC. |
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 06/16/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/09/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/09/2022 |
8-K
| Quarterly results|
Docs:
|
"DESIGN THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2022 2021 Operating expenses: Research and development 8,759 3,875 General and administrative 4,611 1,805 Total operating expenses 13,370 5,680 Loss from operations Other income, net 105 166 Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average shares of common stock outstanding, basic and diluted 55,507,338 17,630,178 DESIGN THERAPEUTICS, INC. CONDENSED BALANCE SHEETS March 31, December 31, 2022 2021 Assets Current assets: Cash, cash equivalents and investment securities $ 371,220 $ 384,064 Prepaid expense and other current assets 2,651 1,371 Total current assets 373,871 385,435 Property and equipment, net 1,448 1,508 Right-of-use asset, related party 3,482 3,614 Total assets $ 37..." |
|
| 04/27/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 04/27/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/22/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 03/10/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/10/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/10/2022 |
8-K
| Quarterly results |
|
|
|